EFG Asset Management’s Viking Therapeutics VKTX Stock Holding History

EFG Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-48,708	Closed	-$1.29M	–	179
2025 Q2	$1.29M	Sell	48,708 -416	-0.8%	-$11K	0.18%	158
2025 Q1	$1.19M	Sell	49,124 -22,649	-32%	-$716K	0.2%	164
2024 Q4	$2.89M	Buy	71,773 +40,674	+131%	+$2.32M	0.39%	100
2024 Q3	$1.97M	Buy	31,099 +12,192	+64%	+$715K	0.33%	136
2024 Q2	$1M	Buy	18,907 +91	+0.5%	+$5.96K	0.17%	179
2024 Q1	$1.54M	Buy	+18,816	New	+$837K	0.27%	152

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

EFG Asset Management's VKTX Position: Q3 2025 in Review

EFG Asset Management sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 48,708 shares — an estimated $1.29M sold.

EFG Asset Management first reported a position in VKTX in Q1 2024 and held it in 6 quarters. The position peaked at $2.89M in Q4 2024. 371 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

EFG Asset Management reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
EFG Asset Management sold 48,708 Viking Therapeutics shares in Q3 2025, an estimated $1.29M.
EFG Asset Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 6 quarters.
EFG Asset Management's Viking Therapeutics position peaked at $2.89M in Q4 2024.
371 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.